Last $115.39 USD
Change Today +1.20 / 1.05%
Volume 1.1M
VRTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

50 Northern Avenue

Boston, MA 02210

United States

Phone: 617-341-6100

Fax:

Vertex Pharmaceuticals Incorporated engages in the discovery, development, manufacture, and commercialization of small molecule drugs for patients with serious diseases in specialty markets. The company markets KALYDECO in the United States and international markets for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have a specific genetic mutation in their CF transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. The company’s business is focused on developing and commercializing therapies for the treatment of CF and advancing its other research and early-stage development programs. CF KALYDECO (ivacaftor) is an orally-administered CFTR potentiator that is approved in the United States, Australia, Canada and the European Union for the treatment of patients six years of age and older with CF who has the G551D mutation in their CFTR gene. The company has submitted a supplemental new drug application to the U.S. Food and Drug Administration, or FDA, and a marketing authorization application, variation in the European Union seeking approval to market ivacaftor for the treatment of patients with CF six years of age and older who have specified other mutations in their CFTR gene, which were studied in its first label-expansion clinical trial for ivacaftor. The company is seeking to expand the number of patients eligible for treatment with ivacaftor by evaluating ivacaftor as a potential treatment for patients with CF who have residual CFTR function, including patients with CF who have the R117H mutation in their CFTR gene, and evaluating ivacaftor as a potential treatment for patients with CF two to five years of age who have specific mutations in their CFTR genes. Ivacaftor in Combination with CFTR Corrector Compounds: In 2013, the company completed enrollment in an international pivotal Phase 3 development program to evaluate combinations of lumacaftor (VX-809), its most advanced investigational CFTR corrector compound, and ivacaftor. The Phase 3 development program includes two Phase 3 clinical trials, referred to as TRAFFIC and TRANSPORT that each enrolled patients with CF 12 years of age and older with two copies (homozygous) of the F508del mutation in their CFTR gene. The company is evaluating VX-661, a second investigational CFTR corrector, in combination with ivacaftor, in Phase 2 clinical development. CF Research Programs: The company is seeking to identify and develop next-generation CFTR corrector compounds that could be evaluated in regimens combining ivacaftor with two CFTR corrector compounds. The company completed a Phase 3 clinical trial to evaluate ivacaftor in patients with the R117H mutation in their CFTR gene. The company is conducting a fully-enrolled proof-of-concept Phase 2 clinical trial in which the company is evaluating ivacaftor in patients with CF who have clinical evidence of residual CFTR function. The company is conducting a fully-enrolled Phase 3 clinical trial in which it is evaluating ivacaftor, in the form of minitablets or granules, as a treatment for children with CF two to five years of age with particular mutations in their CFTR gene, including the G551D mutation. The company is conducting a fully-enrolled proof-of-concept Phase 2 clinical trial in which it is evaluating ivacaftor in patients with CF who have clinical evidence of residual CFTR function. HCV Infection INCIVEK/INCIVO/TELAVIC INCIVEK (telaprevir) is an orally-administered HCV protease inhibitor for adults with genotype 1 HCV infection that is prescribed in combination with peg-IFN and ribavirin (RBV). The company markets INCIVEK in the United States and Canada, where it was approved in 2011. VX-135 The company is evaluating the development of all-oral, interferon-free regimens of 12 weeks or less in duration incorporating its HCV nucleotide analogue NS5B polymerase inhibitor VX-135. Partial Clinical Hold In 2013, the FDA placed a partial clinical hold on VX-135 in the Un

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRTX:US $115.39 USD +1.20

VRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $55.01 USD +0.84
BioMarin Pharmaceutical Inc $89.38 USD -0.07
Jazz Pharmaceuticals PLC $176.65 USD +6.22
Regeneron Pharmaceuticals Inc $415.84 USD +2.84
Sigma-Aldrich Corp $136.53 USD -0.02
View Industry Companies
 

Industry Analysis

VRTX

Industry Average

Valuation VRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.3x
Price/Book 23.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 32.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.